Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2020 | Ixazomib plus chemotherapy for AML & ALL

Amir Fathi, MD, MPH, Massachusetts General Hospital Cancer Center, Boston, MA, discusses results of recent investigations of the addition of ixazomib to chemotherapy in acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) patients. Good tolerability and promising efficacy results support the use of ixazomib. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.